US regulators have approved Moderna's first mRNA-based flu vaccine, mFLUSIVA, for use in all adults aged 50 and older. The approval marks a significant milestone for the biotechnology company, which has been at the forefront of mRNA vaccine development. The vaccine is designed to protect against influenza A and B viruses, offering a new option for older adults who are at higher risk of severe flu complications.
The Food and Drug Administration (FDA) granted full approval to mFLUSIVA after a rigorous review process. This decision comes as flu season approaches, highlighting the importance of vaccination in preventing illness and hospitalization. Moderna's vaccine is expected to be available in the United States later this year, providing an alternative to traditional flu shots.
The approval is based on clinical trial data showing the vaccine's safety and effectiveness in the target population. Moderna has emphasized the potential of mRNA technology to offer more flexible and targeted vaccine development in the future. This approval could influence global flu prevention strategies, particularly in aging populations. (iol.co.za)
